Home > Healthcare > Pharmaceuticals > Finished Drug Form > U.S. Viscosupplementation Market

U.S. Viscosupplementation Market Size

Report ID: GMI10692
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

U.S. Viscosupplementation Market Size

U.S. Viscosupplementation Market size in 2023 was valued at USD 1.1 billion and is set to register growth at 7.6% CAGR from 2024 and 2032. Viscosupplementation offers a minimally invasive treatment option for managing the symptoms of osteoarthritis, such as pain and stiffness, thereby driving its adoption. One of the primary drivers is the rising prevalence of osteoarthritis, particularly in the aging population. As people age, the wear and tear on their joints increase, leading to a higher incidence of osteoarthritis.

To get key market trends

Download Free Sample

Additionally, the growing preference for non-surgical treatments and the increasing demand for pain management solutions contribute to the market's growth. Viscosupplements are seen as a viable alternative to surgery, providing relief to patients without the risks associated with invasive procedures. Moreover, the advancements in viscosupplementation technology, such as the development of more effective formulations and delivery methods, have further expanded the market's potential.

U.S. Viscosupplementation Market Report Attributes
Report Attribute	Details
Base Year:	2023
U.S. Viscosupplementation Market Size in 2023:	USD 1.1 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	7.6%
2032 Value Projection:	USD 2.1 Billion
Historical Data for:	2021 - 2023
No. of Pages:	77
Tables, Charts & Figures:	37
Segments covered:	Product, Source of Origin, and End-use
Growth Drivers:	Growing geriatric population prone to osteoarthritis Rising demand for minimally invasive treatments New product launches Increasing preference for single injection treatment
Pitfalls & Challenges:	High cost of hyaluronic acid treatment Presence of alternatives for knee osteoarthritis treatment

Learn more about the key segments shaping this market

Download Free Sample

Viscosupplementation is widely used for the treatment of osteoarthritis, especially in the knee joint. It involves injecting a gel-like substance called hyaluronic acid into the joint to provide lubrication and cushioning. Hyaluronic acid is a naturally occurring substance found in the synovial fluid that surrounds joints, acting as a lubricant and shock absorber. In osteoarthritis, the synovial fluid becomes thinner and less effective, leading to increased friction and pain in the joint. By injecting hyaluronic acid directly into the joint, viscosupplementation aims to restore the viscosity and elasticity of the synovial fluid, reducing pain and improving joint function.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

U.S. viscosupplementation market size was USD 1.1 billion in 2023 and is expected to register 7.6% CAGR from 2024-2032 owing to the rising prevalence of osteoarthritis, particularly in the aging population.

U.S. viscosupplementation industry from the 3 injections segment held 45.6% share in 2023 due to being supported by robust clinical evidence demonstrating its effectiveness in relieving symptoms of osteoarthritis and improving joint function.

U.S. viscosupplementation market from the non-avian segment is expected to reach USD 1.6 billion by 2032 due to reduced risk of allergic reactions, ethical and environmental considerations, and the assurance of consistency and purity with non-avian variety.

Bioventus Inc., Ferring Pharmaceutical, Fidia Farmaceutici S.p.A (Fidia Pharma USA Inc.), Lifecore Biomedical, Inc, Pacira BioSciences, Inc, Sanofi SA, Seikagaku Corporation, and Teva Pharmaceutical Industries Ltd., are some of the major viscosupplementation companies from the U.S.